Outlook Therapeutics, Inc. OTLK
Set alert
At close
Pre-market · Nov 3, 7:38 AM ET
- YTD
- -70.30%
- 1 year
- -63.91%
- Open
- 0.4691
- Prev close
- 0.4681
- Mkt cap
- 114.23M
- Vol
- 2.28M
- Avg vol
- 10.14M
- EPS
- -0.70
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.4457
- High
- 0.4817
- Forward P/E
- -0.55
- Beta
- 0.63
- Short ratio
- 1.26
- Inst. own
- 35.63%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 27, 2024
- 50-d avg
- 4.24
- 200-d avg
- 6.73
- 1y target
- 24.80
5D chart
Signals (109)
| Name | Time | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 9:40 AM | 22 hours ago |
| SMA: Bullish | Nov 2, 9:35 AM | 22 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 22 hours ago |
| SMA: Bearish | Nov 2, 9:30 AM | 22 hours ago |
| SMA: Bullish | Oct 30, 3:05 PM | 3 days ago |
| SMA: Bullish | Oct 30, 2:50 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 2:45 PM | 3 days ago |
| RSI: Oversold | Oct 30, 2:20 PM | 3 days ago |
| RSI: Oversold | Oct 30, 1:35 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:30 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:25 PM | 3 days ago |
| SMA: Bullish | Oct 30, 1:20 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 1:20 PM | 3 days ago |
| SMA: Bearish | Oct 30, 1:00 PM | 3 days ago |
| MACD: Sell Signal | Oct 30, 1:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 30, 12:25 PM | 3 days ago |
| SMA: Bearish | Oct 30, 11:25 AM | 3 days ago |
| RSI: Oversold | Oct 30, 11:25 AM | 3 days ago |
| SMA: Bearish | Oct 30, 10:25 AM | 3 days ago |
| SMA: Bullish | Oct 30, 10:20 AM | 3 days ago |
Newest 20 of 109.
News
-
1 month ago benzinga.com
Outlook Therapeutics Files Application With Centers For Medicare & Medicaid Services Seeking Healthcare Common Procedure Coding System Level II J-Code For LYTENAVA To Treat Macular Degeneration
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of retinal…
-
1 month ago benzinga.com
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10.5
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $10 to $10.5.
2 months ago benzinga.com
5 Stocks In The Spotlight Last Week: Wall Street's Most Accurate Analysts Weigh In
U.S. stocks fell, but S&P 500 gained 0.4% for 3rd week. Wall Street analysts make new stock picks daily, Benzinga's data can help make better trades.
-
2 months ago benzinga.com
BTIG Reiterates Buy on Outlook Therapeutics, Maintains $4 Price Target
BTIG analyst Julian Harrison reiterates Outlook Therapeutics (NASDAQ:OTLK) with a Buy and maintains $4 price target.
2 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers MDxHealth (NASDAQ:MDXH) stock moved upwards by 120.8% to $1.02 during Friday's regular session. The company's market cap stands at $23.7 million. The company's, Q2 earnings came out yesterday.
2 months ago benzinga.com
Transcript: Outlook Therapeutics Q3 2026 Earnings Conference Call
Outlook Therapeutics (NASDAQ:OTLK) released third-quarter financial results and hosted an earnings call on Friday. Read the complete transcript below. This transcript is brought to you by Benzinga…
-
2 months ago benzinga.com
Outlook Therapeutics Q3 Adj. EPS $(0.09), Inline, Sales $9.000K Miss $5.300M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 79.55 percent increase over losses of $(0.44) per share from the…
2 months ago benzinga.com
S&P 500 Hits New Record High Following PPI Data: Investor Sentiment Improves, Fear Index Remains In ‘Greed’ Zone
CNN Fear & Greed index showed improved market sentiment, with S&P 500 hitting a new record high after PPI data release. Nasdaq up 0.81%.
2 months ago benzinga.com
Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Outlook Therapeutics (NASDAQ: OTLK) to release Q3 earnings on Aug. 14. Analysts expect a loss of 8 cents/share. Analysts rate it Neutral or Buy.
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock increased by 48.4% to $0.16 during Thursday's regular session. The market value of their outstanding shares is at $7.2 million. BeyondSpring (NASDAQ:BYSI)…
2 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…
-
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock…
-
2 months ago benzinga.com
Outlook Therapeutics Launches Underwritten Public Offering Of Common Stock And Warrants To Fund LYTENAVA Launch; No Financial Terms Disclosed
Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for…
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $97.4 million. Prelude Therapeutics (NASDAQ:PRLD)…
-
3 months ago benzinga.com
HC Wainwright & Co. Maintains Neutral on Outlook Therapeutics, Raises Price Target to $1.6
HC Wainwright & Co. analyst Douglas Tsao maintains Outlook Therapeutics (NASDAQ:OTLK) with a Neutral and raises the price target from $0.5 to $1.6.
-
3 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Entera Bio (NASDAQ:ENTX) stock moved upwards by 86.6% to $3.83 during Monday's regular session. The company's market cap stands at $100.9 million. Gossamer Bio (NASDAQ:GOSS) shares moved…
3 months ago benzinga.com
Outlook Therapeutics Targets Multibillion Dollar Ophthalmology Market With New Drug After FDA Rejection
The FDA approved LYTENAVA by Outlook Therapeutics, marking the first ophthalmic bevacizumab for wet AMD in the lucrative US retina market.
3 months ago benzinga.com
This General Motors Analyst Turns Bulish; Here Are Top 5 Upgrades For Monday
Wall Street analysts upgrade GM, RIVN, OTLK, F, and MBLY. See their ratings on Benzinga's analyst ratings page before buying.
-
3 months ago benzinga.com
BTIG Upgrades Outlook Therapeutics to Buy, Announces $4 Price Target
BTIG analyst Julian Harrison upgrades Outlook Therapeutics (NASDAQ:OTLK) from Neutral to Buy and announces $4 price target.
-
3 months ago benzinga.com
Outlook Therapeutics Says FDA Approves LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration, Commonly Known As Wet AMD
Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and…
4 months ago benzinga.com
Outlook Therapeutics Eye Drug Review Returns To FDA For Fourth Time
Outlook Therapeutics shares rose after the FDA accepted its resubmitted LYTENAVA BLA and set a July 2026 target action date.
4 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
4 months ago benzinga.com
Outlook Therapeutics Says FDA Accepts Resubmitted BLA For ONS-5010/LYTENAVA For Treatment Of Neovascular Age-Related Macular Degeneration; PDUFA Target Action Date July 29
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the U.S. Food and…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
4 months ago benzinga.com
Intel To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed outlook on top names. See full list of rating changes on analyst ratings page: CHEF, NAVN, INTC, HOOD, GPCR, OTLK, ORCL.
-
4 months ago benzinga.com
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $6 to $10.
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
12 Health Care Stocks Moving In Monday's Intraday Session
-
5 months ago benzinga.com
Outlook Therapeutics Resubmits Biologics License Application To FDA For ONS-5010/LYTENAVA To Treat Neovascular Age-Related Macular Degeneration
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
-
5 months ago benzinga.com
Outlook Therapeutics Announces $5M Registered Direct Offering Of 8,539,709 Shares At $0.5855/Share To GMS Ventures For Working Capital And General Corporate Purposes
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of…
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
5 months ago benzinga.com
Outlook Shares Jump Following FDA Appeal Decision For LYTENAVA
Outlook Therapeutics Inc. shares are trading higher Tuesday after the FDA granted its appeal in the ONS-5010 dispute resolution process.
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
5 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
5 months ago benzinga.com
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Wall Street analysts changed ratings on top stocks. Check out the complete list on Benzinga's analyst ratings page. AMAT was downgraded.
-
5 months ago benzinga.com
Outlook Therapeutics Q2 Adj. EPS $(0.16) Misses $(0.12) Estimate, Sales $128.000K Miss $4.400M Estimate
Outlook Therapeutics (NASDAQ:OTLK) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 60 percent increase over losses of…
-
5 months ago benzinga.com
Outlook Therapeutics Terminates Offering Agreement With BTIG Effective May 12
Effective May 12, 2026, Outlook Therapeutics canceled its at-the-market sales agreement, dated as of May 16, 2023 (as amended, the "Prior Sales Agreement") with BTIG, LLC with respect to an…
-
5 months ago benzinga.com
Outlook Therapeutics Enter $100M Offering Agreement With H.C. Wainwright
On May 13, 2026, Outlook Therapeutics, Inc. (the "Company") entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC ("H.C. Wainwright"), pursuant to…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
-
6 months ago benzinga.com
Outlook Therapeutics Completes Federal Dispute Resolution Meeting With The Office Of New Drugs At FDA For Regulatory Nod For ONS-5010 / LYTENAVA
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that it has…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
7 months ago benzinga.com
Crude Oil Gains Around 4%; US Business Activity Declines In March
U.S. stocks fall with Dow down 0.46%, S&P 500 down 0.52%, NASDAQ down 0.89%. Energy up 2.5%, communication services down 1.2%.
7 months ago benzinga.com
Dow Falls Over 350 Points; Core & Main Posts Mixed Q4 Results
US stocks lower on Tuesday as Dow falls over 350 points while NASDAQ and S&P 500 also decline. Energy shares up 1.7%, tech stocks down 1.1%.
-
7 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
7 months ago benzinga.com
Why Paranovus Entertainment Technology Shares Are Trading Higher By Around 66%; Here Are 20 Stocks Moving Premarket
PAVS stock rose 65.6% in pre-market trading after ending sales agreement with A.G.P/Alliance Global Partners and other stocks moved.
7 months ago benzinga.com
Uniqure To Rally Around 92%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on top names. See all changes on analyst ratings page.
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session